SCHEMBL169110

SCHEMBL169110

Fc1ccc([C@@H]2CCCN2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.50
CHRNA7 P36544 2/20 0.50
CHRNA4 P43681 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
MKNK1 Q9BUB5 1/20 0.47
KCNH2 Q12809 1/20 0.46
MEN1 O00255 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2A6 P11509 1/20 0.44
CYP2C9 P11712 1/20 0.44
PARP1 P09874 2/20 0.43
CHRM5 P08912 5/20 0.43
CHRM3 P20309 5/20 0.43
CHRM2 P08172 5/20 0.43
CHRM1 P11229 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6179150 1.00 CHRNB2 (0.50) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
SCHEMBL169111 1.00 CHRNB2 (0.50) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
Hydrochloric Acid SCHEMBL3335334 0.98 CHRNB2 (0.49) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
Hydrochloric Acid SCHEMBL28608773 0.98 CHRNB2 (0.49) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
Hydrochloric Acid SCHEMBL3335329 0.98 CHRNB2 (0.49) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
SCHEMBL938791 0.94 MEN1 (0.51) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
SCHEMBL938782 0.94 MEN1 (0.51) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
SCHEMBL19156 0.94 MEN1 (0.51) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
SCHEMBL8541058 0.92 MEN1 (0.50) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1
Hydrochloric Acid SCHEMBL1764829 0.92 MEN1 (0.50) CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025060911-A1 SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 成都奥睿药业有限公司 2025-03-27 WO disclosed
CN-118878535-A Substituted pyridotriazole compound, preparation method and application thereof 成都奥睿药业有限公司 2024-11-01 CN disclosed
US-20230365546-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF ORIGIANT PHARMACEUTICAL CO., LTD (CN) 2023-11-16 US disclosed
EP-4212525-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF Origiant Pharmaceutical Co., Ltd (CN) 2023-07-19 EP disclosed
US-8669266-B2 Quinoline-carboxamide derivatives as P2Y12 antagonists SANOFI (FR) 2014-03-11 US disclosed
EP-2487154-B1 Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods BRISTOL MYERS SQUIBB CO (US) 2013-10-16 EP disclosed
EP-2611441-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2013-07-10 EP disclosed
CN-103079562-A BACE inhibitors for use in the treatment of diabetes HOFFMANN LA ROCHE 2013-05-01 CN disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 WO disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
EP-1943215-A2 PYRROLIDINYL BETA-AMINO AMIDE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS Brystol-Myers Squibb Company (US) 2008-07-16 EP disclosed
EP-1910317-A1 1-AMINO LINKED COMPOUNDS Eli Lilly and Company (US) 2008-04-16 EP disclosed
WO-2007053819-A2 PYRROLIDINYL BETA-AMINO AMIDE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-10 WO disclosed
US-20070099913-A1 To treat diabetes, especially type II diabetes including complications of diabetes; synergistic BRISTOL-MYERS SQUIBB COMPANY 2007-05-03 US disclosed
WO-2007015805-A1 1-AMINO LINKED COMPOUNDS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed
EP-1165510-B1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
EP-1165510-A1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-02 EP disclosed
US-6284785-B1 HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS HOFFMANN- LA ROCHE INC. 2001-09-04 US disclosed
WO-2000058285-A1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 CHRNB2 2140/4885CHRNA7 1470/4885CHRNA4 679/4885
US-20230365546-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF RIPK1, RIPK3, RIPK2 CHRNB2 3758/4885CHRNA7 2486/4885CHRNA4 3557/4885
US-20070099913-A1 To treat diabetes, especially type II diabetes including complications of diabetes; synergistic GLP1R, GPR119, SLC5A2 CHRNB2 2384/4885CHRNA7 3389/4885CHRNA4 3245/4885
US-20120053200-A1 BACE 2 INHIBITORS BACE2, BACE1, PSEN2 CHRNB2 382/4885CHRNA7 1631/4885CHRNA4 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.